UBS Group’s Comera Life Sciences Holdings, Inc. Common Stock CMRA Stock Holding History

UBS Group’s Portfolio CMRA Stock Details CMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-8,017	Closed	-$2.33K	–	10420
2023 Q3	$2.33K	Buy	8,017 +6,366	+386%	+$3.36K	﹤0.01%	7725
2023 Q2	$804	Sell	1,651 -408	-20%	-$262	﹤0.01%	8091
2023 Q1	$1.85K	Buy	2,059 +826	+67%	+$1.04K	﹤0.01%	8634
2022 Q4	$1.52K	Sell	1,233 -1,394	-53%	-$2.04K	﹤0.01%	9851
2022 Q3	$4K	Sell	2,627 -535	-17%	-$1.28K	﹤0.01%	9448
2022 Q2	$8K	Buy	+3,162	New	+$10.5K	﹤0.01%	8400

UBS Group's CMRA Position: Q4 2023 in Review

UBS Group sold out of Comera Life Sciences Holdings, Inc. Common Stock (CMRA) in Q4 2023, closing a stake of 8,017 shares — an estimated $2.33K sold.

UBS Group first reported a position in CMRA in Q2 2022 and held it in 6 quarters. The position peaked at $8K in Q2 2022. 0 funds tracked by Wall St. Rank hold CMRA as of Q4 2023.

UBS Group reported no remaining Comera Life Sciences Holdings, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
UBS Group sold 8,017 Comera Life Sciences Holdings, Inc. Common Stock shares in Q4 2023, an estimated $2.33K.
UBS Group first reported a position in Comera Life Sciences Holdings, Inc. Common Stock in Q2 2022 and held it in 6 quarters.
UBS Group's Comera Life Sciences Holdings, Inc. Common Stock position peaked at $8K in Q2 2022.
0 funds tracked by Wall St. Rank held Comera Life Sciences Holdings, Inc. Common Stock as of Q4 2023.

Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.